The New Antipsychotics and Their Therapeutic Potential

Keck, Paul E.; McElroy, Susan L.

doi:10.3928/0048-5713-19970501-04

Cited by 16 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of these medications is limited primarily to the amelioration of positive (overt) symptoms of psychosis (hallucinations, delusions, thought disorder) [2]. Typical antipsychotics have a number of clinical limitations; limited efficacy in negative (deficit) symptoms, lack of efficacy in 20 -40% of patients with schizophrenia, and bothersome neurological, neurendocrinological and other systemic side effects [3].…”

Section: Introductionmentioning

confidence: 99%

Ziprasidone: a new atypical antipsychotic

2001

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.

show abstract

Section: Introductionmentioning

confidence: 99%